ENZC (Enzolytics) Other Current Payables: $0.26 Mil (As of Jun. 2011)


What is Enzolytics Other Current Payables?

Enzolytics ENZC -12.50% Other Current Payables is $0.26 Mil as of Jun. 2011.

Enzolytics's Other Current Payables for the quarter that ended in Jun. 2011 was $0.26 Mil.

Enzolytics's quarterly Other Current Payables increased from Dec. 2010 ($0.04 Mil) to Mar. 2011 ($0.10 Mil) and increased from Mar. 2011 ($0.10 Mil) to Jun. 2011 ($0.26 Mil).

Enzolytics's annual Other Current Payables increased from Jul. 2008 ($0.00 Mil) to Dec. 2009 ($0.50 Mil) but then declined from Dec. 2009 ($0.50 Mil) to Dec. 2010 ($0.04 Mil).

Enzolytics Other Current Payables Related Terms

Enzolytics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Enzolytics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzolytics Other Current Payables Chart

Enzolytics Annual Data
Trend Dec07 Jul08 Dec09 Dec10
Other Current Payables
0.05 0.00 0.50 0.04

Enzolytics Quarterly Data
Sep07 Dec07 Apr08 Jul08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.05 0.04 0.10 0.26

Enzolytics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.26 Mil mean?
Enzolytics (ENZC) has a Other Current Payables of $0.26 Mil as of Jun. 2011. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Enzolytics and its competitors.
Is Enzolytics' Other Current Payables too high?
Enzolytics' current Other Current Payables is $0.26 Mil.
How does Enzolytics' Other Current Payables compare to competitors?
Enzolytics' Other Current Payables of $0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Enzolytics and its competitors. Enzolytics's current Other Current Payables is $0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzolytics stock overvalued right now?
Enzolytics (ENZC) has a current Other Current Payables of $0.26 Mil. The current Other Current Payables is $0.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Enzolytics (ENZC), the current Other Current Payables is $0.26 Mil as of Jun. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Enzolytics Business Description

Address 1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013
Enzolytics Inc is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The company is committed to creating drugs for the good health of mankind. ENZC's flagship compound, ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use.